






Q2 2023 Business and Financial Presentation

August 8, 2023

© Veracyte, Inc. All rights reserved.



Forward-looking statements and non-GAAP information

This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue for 2023 and other financial and operating results and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our tests and products, including our biopharma atlas, for use in diagnosing and treating diseases, and our commercial organization. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “positioned,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; to demonstrate the validity and utility of our genomic tests and biopharma offerings; to continue to integrate and expand the HaliDx and Decipher businesses and execute on our business plans; to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine on European economies and energy supply, as well as our facilities in France; the impact of the COVID-19 pandemic and its variants on our business and general economic conditions; the impact of foreign currency fluctuations, increasing interest rates, and inflation, and turmoil in the global banking and finance system; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed for the year ended December 31, 2022, and our Quarterly Report on Form 10-Q for the three months ended June 30, 2023, to be filed with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at www.investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation contains certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, and non-GAAP loss from operations. These measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. We use non-GAAP measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP measures we present may be different from those used by other companies.

We exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences and HaliDx and costs related to restructuring from certain of our non-GAAP measures. Management has excluded the effects of these items in non-GAAP measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between our GAAP results and non-GAAP financial measures are presented in the Appendix.

Veracyte, the Veracyte logo, Decipher, Afirma, Percepta, Envisia, Prosigna, Lymphmark, TMExplore, Brightplex, Immunosign, “Know by Design” and “More about You” are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. Immunoscore IC® is a trademark of Veracyte SAS registered in France. Immunoscore is a registered trademark of Inserm used by Veracyte under license. nCounter is the registered trademark of NanoString Technologies used by Veracyte under license.

Key Q2 2023 Results and FY 2023 Outlook

1. **Strong Q2 2023 revenue of \$90.3M** driven by Decipher Prostate and Afirma
2. **Ended Q2 with \$191M of cash,¹** and generated ~\$17M of cash from operations during the quarter
3. **Presented 12 abstracts** on our diagnostic tests and biopharmaceutical offerings, demonstrating our commitment to advance the scientific understanding of diseases we address
4. **Raised 2023 revenue guidance to \$342M to \$350M²** based on testing revenue growth in the mid-twenties

1. As of June 30, 2023, includes cash, cash equivalents and short-term investments
2. Guidance as of August 8, 2023 only; assumes currency exchange rates as of August 8, 2023





**Our vision is to
transform cancer
care for patients
all over the world.**





OUR PURPOSE

We believe exceptional cancer care begins with **exceptional diagnostics**

OUR PROMISE

We empower clinicians with the high-value insights they need to **guide and assure patients at pivotal moments in the race to diagnose and treat cancer**



Our proven framework for developing successful tests

1

Identify clinical unmet needs

through collaboration with customers. We focus on oncology where we help inform diagnosis, prognosis and treatment decisions

2


Develop high-performance tests

using deep scientific, clinical and machine-learning expertise and capabilities

3


Drive adoption

through KOL support, evidence development, guideline inclusion, reimbursement and market development




Delivered Q2 total revenue growth of 24%

Total Revenue by Quarter¹




Total Volume by Quarter




1. Amounts in millions; Testing, Product and BioPharma and Other revenue rounded and summarized as presented

Strong Non-GAAP gross margin

Non-GAAP Gross Margin by Quarter¹



Non-GAAP Operating Expense by Quarter^{1,2}




1. Non-GAAP reconciliations available in the appendix of this presentation
 2. Amounts in millions; Operating expenses rounded and summarized as presented

Cash balance of \$191M¹

- Record Q2 cash generated by operations of \$16.7M
- Testing growth and working capital performance resulted in higher than projected cash balance
- 2023 outlook:
 - Raising expectations for ending 2023 cash balance to \$190M²

Cash balance¹




1. Ending balance of cash, cash equivalents and short-term investments, excluding restricted cash, in millions

2. Guidance as of August 8, 2023, reposting should not be considered a reiteration of guidance; excludes the impact of potential M&A

Raising 2023 revenue guidance to \$342M to \$350M







- Reflects testing growth of mid-twenties YoY
- Projecting 2023 biopharma and other revenue of between \$18M - \$19M



1. Testing, Product and Biopharma and other revenue rounded and summarized as presented in millions
 2. Guidance and currency rates are as of August 8, 2023; reposting should not be considered a reiteration of guidance
 3. 2021 included \$4M JNJ milestone



Increased guidance in revenue and cash

	Updated Guidance ¹		Prior Guidance ²
Total revenue	\$342M - \$350M		\$330M - \$340M
Testing revenue growth	Mid-twenties		Mid-to-high teens
Afirma revenue growth	Low-to-mid teens		High-single digits
Biopharma and other revenue	\$18M - \$19M		
Gross margin	Mid-to-high 60's		Mid-60's
2023 Ending Cash ³	\$190M including contingent consideration⁴		~\$180M including contingent consideration ⁴

1. Guidance and currency rates are as of August 8, 2023, reposting should not be considered a reiteration of guidance

2. Prior guidance provided on May 4, 2023

3. Cash, cash equivalents and short-term investments, excludes the impact of potential M&A

4. The impact of prior acquisition related contingent consideration payments

Q2 2023

Reconciliation of Non-GAAP Financial Measures

(Unaudited)
(In thousands of dollars)

	GAAP	Identified Expenses			Total Non-GAAP Measure
		Acquisition Related Expenses (1)	Intangible Assets Amortization Expense	Other (4)	
Three Months Ended June 30, 2023					
Total revenue	\$ 90,322	\$ —	\$ —	\$ —	\$ 90,322
Cost of testing revenue	23,333	—	—	—	23,333
Cost of product revenue	2,315	—	—	—	2,315
Cost of biopharmaceutical and other revenue	4,040	25	—	—	4,015
Intangible asset amortization (2)	4,814	—	4,814	—	—
Gross margin \$	55,820	25	4,814	—	60,659
Gross margin %	62 %				67 %
Research and development	12,541	17	—	—	12,524
Selling and marketing	25,756	889	—	—	24,867
General and administrative	25,047	1,720	—	1,437	21,890
Intangible asset amortization	527	—	527	—	—
Total operating expenses excluding cost of revenue (3)	63,871	2,626	527	1,437	59,281
Loss from operations	\$ (8,051)	\$ 2,651	\$ 5,341	\$ 1,437	\$ 1,378

1. Includes transaction related expenses as well as post-combination compensation expenses. For each of the three months ended June 30, 2022, and June 30, 2023, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HaliuDx.
2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.
3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$29.7 million and \$25.0 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.8 million and \$4.9 million) for the three months ended June 30, 2023 and for the three months ended June 30, 2022 respectively.
4. For the three months ended June 30, 2022, \$3.3 million expense included related to the impairment charge associated with certain developed technology intangible assets. For the three months ended June 30, 2023, includes \$1.4 million related to the departure of the former executive chair.

Q1 2023

Reconciliation of Non-GAAP Financial Measures

(Unaudited)
(In thousands of dollars)

	GAAP	Identified Expenses			Total Non-GAAP Measure
		Acquisition Related Expenses (1)	Intangible Assets Amortization Expense	Other (4)	
Three Months Ended March 31, 2023					
Total revenue	\$ 82,422	\$ —	\$ —	\$ —	\$ 82,422
Cost of testing revenue	19,648	83	—	—	19,565
Cost of product revenue	2,162	—	—	—	2,162
Cost of biopharmaceutical and other revenue	4,419	43	—	—	4,376
Intangible asset amortization (2)	4,804	—	4,804	—	—
Gross margin \$	51,389	126	4,804	—	56,319
Gross margin %	62 %				68 %
Research and development	12,769	24	—	—	12,745
Selling and marketing	26,130	890	—	—	25,240
General and administrative	22,463	1,036	—	1,344	20,083
Intangible asset amortization	525	—	525	—	—
Total operating expenses excluding cost of revenue (3)	61,887	1,950	525	1,344	58,068
Loss from operations	\$ (10,498)	\$ 2,076	\$ 5,329	\$ 1,344	\$ (1,749)

1. Includes transaction related expenses as well as post-combination compensation expenses, adjustments consist primarily of post-combination compensation expenses associated with the acquisition of HaliuDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$26.2 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.8 million).

4. Includes impairment charge associated with Richmond.

Q4 2022

Reconciliation of Non-GAAP Financial Measures

(Unaudited)
(In thousands of dollars)

	GAAP	Identified Expenses			Total Non-GAAP Measure
		Acquisition Related Expenses (1)	Intangible Assets Amortization Expense	Other	
Three Months Ended December 31, 2022					
Total revenue	\$ 80,297	\$ —	\$ —	\$ —	\$ 80,297
Cost of testing revenue	19,394	50	—	—	19,344
Cost of product revenue	2,618	—	—	—	2,618
Cost of biopharmaceutical and other revenue	4,819	64	—	—	4,755
Intangible asset amortization (2)	4,747	—	4,747	—	—
Gross margin \$	48,719	114	4,747	—	53,580
Gross margin %	61 %				67 %
Research and development	11,287	232	—	—	11,055
Selling and marketing	24,127	917	—	—	23,210
General and administrative	18,208	1,368	—	—	16,840
Intangible asset amortization	517	—	517	—	—
Total operating expenses excluding cost of revenue (3)	54,139	2,517	517	—	51,105
Income (loss) from operations	\$ (5,420)	\$ 2,631	\$ 5,264	\$ —	\$ 2,475

1. Includes transaction related expenses as well as post-combination compensation expenses consisting primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$26.8 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.7 million).

Q3 2022

Reconciliation of Non-GAAP Financial Measures

(Unaudited)
(In thousands of dollars)

	GAAP	Identified Expenses			Total Non-GAAP Measure
		Acquisition Related Expenses (1)	Intangible Assets Amortization Expense	Other (4)	
Three Months Ended September 30, 2022					
Total revenue	\$ 75,592	\$ —	\$ —	\$ —	\$ 75,592
Cost of testing revenue	19,816	49	—	18	19,749
Cost of product revenue	1,981	—	—	3	1,978
Cost of biopharmaceutical and other revenue	4,211	62	—	—	4,149
Intangible asset amortization (2)	4,703	—	4,703	—	—
Gross margin \$	44,881	111	4,703	21	49,716
Gross margin %	59 %				66 %
Research and development	10,773	251	—	—	10,552
Selling and marketing	25,678	923	—	493	24,262
General and administrative	17,600	1,272	—	—	16,328
Intangible asset amortization	510	—	510	—	—
Total operating expenses excluding cost of revenue (3)	54,561	2,446	510	493	51,112
Loss from operations	\$ (9,680)	\$ 2,557	\$ 5,213	\$ 514	\$ (1,396)

1. Includes transaction related expenses as well as post-combination compensation expenses consisting primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$26.0 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.7 million).

4. Includes \$0.5 million expense related to restructuring costs.

Q2 2022

Reconciliation of Non-GAAP Financial Measures

(Unaudited)
(In thousands of dollars)

	GAAP	Identified Expenses			Total Non-GAAP Measure
		Acquisition Related Expenses (1)	Intangible Assets Amortization Expense	Other (4)	
Three Months Ended June 30, 2022					
Total revenue	\$ 72,864	\$ —	\$ —	\$ —	\$ 72,864
Cost of testing revenue	18,584	51	—	—	18,533
Cost of product revenue	1,646	—	—	—	1,646
Cost of biopharmaceutical and other revenue	4,800	65	—	—	4,735
Intangible asset amortization (2)	4,869	—	4,869	—	—
Gross margin \$	42,965	116	4,869	—	47,950
Gross margin %	59 %				66 %
Research and development	9,377	293	—	—	9,084
Selling and marketing	24,001	858	—	—	23,143
General and administrative	19,798	(285)	—	3,318	16,765
Intangible asset amortization	522	—	522	—	—
Total operating expenses excluding cost of revenue (3)	53,698	866	522	3,318	48,992
Income (loss) from operations	\$ (10,733)	\$ 982	\$ 5,391	\$ 3,318	\$ (1,042)

1. Includes transaction related expenses as well as post-combination compensation expenses consisting primarily of post-combination compensation expenses associated with the acquisition of HalioDx.

2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue.

3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue (\$25.0 million) and the amortization of intangible assets which would have been allocated to the cost of revenue (\$4.9 million).

4. Includes \$3.3 million expense related to the impairment charge associated with certain developed technology intangible assets.